1224 ET - Bluebird bio's deal to be taken private will leave investors with a rich reward or a steep haircut, depending on sales of the company's gene therapies over the next three years. Analysts at William Blair think it will be the latter. Bluebird holders will get an initial $3 a share, 57% below Thursday's closing price, but contingent value rights that would be triggered by 12-month sales of $600 million would bring another $6.84 a share, for a 40% premium. William Blair says it currently models bluebird's sales reaching only $546.4 million in 2027, making the probability of achieving the CVR contingency low. Bluebird slide 39% to $4.29. (colin.kellaher@wsj.com)
(END) Dow Jones Newswires
February 21, 2025 12:24 ET (17:24 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。